| | |
| Clinical data | |
|---|---|
| Routes of administration | Intramuscular injection |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H16Cl2N4O3 |
| Molar mass | 359.21 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Asoxime chloride, or more commonly HI-6, is a Hagedorn oxime used in the treatment of organophosphate poisoning. [1]
HI-6 was developed in the 1968 in Ilse Hagedorn [2] 's lab at the University of Freiburg in then West Germany as a potent antidote for poisoning by organophosphorus nerve agents. [3] The compound was created in response to limitations of earlier oxime antidotes, which were effective against some nerve agents but failed to protect against others such as soman. [4]
Much line pralidoxime, asoxime and other oximes created in the Hagedorn lab (i.e. LüH-6, HLö-7) are pyridine oximes, sharing the same structural feature of a byspyridinium nucleus. Position 2 and 4 on one of the pyridine rings is essential for pharmacological activity, as is position 4 on the second ring for both efficacy and toxic effects alike. Amidation on the second ring at position 4 is essential for reducing toxicity of the derivative compounds [5] .
{{cite book}}: CS1 maint: location (link)